Scientific notes

Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium

Immune Checkpoint Modulators as an emerging therapy

Through this paper, Kim and colleagues highlight the way that immune checkpoint modulators are exploited by tumor cells to decrease immune activation and antigen recognition. Therefore, these checkpoint modulators can also be a powerful tool to improve cancer therapy. It is a non-specific strategy that consists of a generalized activation of the immune system that can be combined with chemotherapy and/or radiation therapy. Indeed, monoclonal antibodies such as anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab), can be used to target checkpoint inhibitors for a therapeutic blockade. Both are already in phase 4 of clinical development but there are many other targets known as LAG-3, TIM-3, KIR, and GITR which are in phase 1 or 2.

Check Point modulator validation system dedicated system to cell-cell interactions follow-up

How to culture vascularized & immunocompetent 3D models in a standard Multiwell

Summary

Immune checkpoints have come to the forefront of cancer therapies as a powerful and promising strategy to stimulate antitumor T cell activity. Results from recent preclinical and clinical studies demonstrate how checkpoint inhibition can be utilized to prevent tumor immune evasion and both local and systemic immune suppression. This review encompasses the key immune checkpoints that have been found to play a role in tumorigenesis and, more specifically, gliomagenesis. The review will provide an overview of the existing preclinical and clinical data, antitumor efficacy, and clinical applications for each checkpoint with respect to GBM, as well as a summary of combination therapies with chemotherapy and radiation.

References

Related Posts

Sentinel Lymph Nodes (SLN) Biopsies: Clinical Aspects...
Context The lymphatic system is approximately omnipresent in the human body and present in most human tissues excluding cartilage, eye lens,...
Read more
Melanoma Immunotherapy and Precision Medicine in the Era of Tumor...
Introduction Melanoma is clearly a complex disease with a high degree of heterogeneity and adaptability. Melanoma cells are part of a larger...
Read more
Tumor_targeting
3D cell culture and anticancer drug testing...
Efficacity and toxicity of candidate anticancer drugs on 3D cell culture model has been much lower than on 2D cell culture models over the p...
Read more

get in touch

Get the best insights about Cherry Biotech by Email Let’s stay in touch!
As part of our commercial prospecting, we may need to process your personal data. For more information, please consult our Privacy Policy